Fundraising Fox
Verseau Therapeutics
Auburndale, US · Founded 2017 · Delaware corporation · 6 employees on LinkedIn · 4 known investors
Find your way into Verseau Therapeutics
Sign up to see every warm intro you have to Verseau Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Verseau Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.
Founders & leadership
Verseau Therapeutics was founded in 2017 by Bob Langer, Dan Anderson, Tatiana Novobrantseva, and Igor Feldman.
BL
Bob LangerCo-founder
DA
TN
Tatiana NovobrantsevaTatiana Novobrantseva has worked across drug development modalities including protein and nucleic acid therapeutics, with experience in immunology, inflammation, and immuno-oncology programs. She has held operational and advisory roles at biotech startups focused on bringing novel medicines to patients.
IF
Igor FeldmanIgor Feldman is a computational biologist who co-founded Verseau Therapeutics and previously led clinical and translational bioinformatics at Moderna, where he supported oncology programs including personalized cancer vaccines using multi-omics data. He has also advised AI-focused biotech companies on translational strategy and computational biology platform development.
WC
Walter CaponeExecutive
CB
Christine BuntChief Executive Officer, Chairman of the Board, Senior Advisor2017–2021Christine Bunt is Executive Chairman and CEO of Verseau Therapeutics, which she co-founded with professors from MIT; she previously founded and led TARIS Biomedical (acquired by Allergan and J&J) and INTICA Biomedical, and held senior commercial roles at Merck and Roche. She holds degrees in Medical Technology and Immunochemistry from the University of Saarbrücken and has completed executive education at INSEAD and Harvard.
Board
JC
Jong ChangBoard director
Investors · 4
20/20 HealthCare Partners LLClisted by 20/20 HealthCare Partners LLCAuburndalevia Hillel Bachrach · led
How we know: 20/20 HealthCare Partners LLC's portfolio page · Not right? Tell us
Highlight CapitalreportedNanjin
How we know: funding news · dealstreetasia.com · Not right? Tell us
Also in the syndicate · 1
3SBio
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 1 of 2 rounds · 2017–2019
▶$4.3MraisedMar 2017 · 5 investors · Other Health CareRule 506(b)
▶$4.3MraisedMar 2017 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel AndersonExecutive Officer, Director, Promoter
- Walter CaponeExecutive Officer
- Robert LangerDirector, Promoter
- Jong ChangDirector
- Christine BuntExecutive Officer, Director
- Offering amount
- $11.4M
- Amount sold
- $4.3M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
VeratxVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Vivace TherapeuticsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Edgewise TherapeuticsEdgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies working in the same space as Verseau Therapeutics.
In the news
Frequently asked questions
- What does Verseau Therapeutics do?
- Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.
- Who founded Verseau Therapeutics?
- Verseau Therapeutics was founded by Bob Langer, Dan Anderson, Tatiana Novobrantseva, Igor Feldman in 2017.
- Who are Verseau Therapeutics's investors?
- Verseau Therapeutics's investors include 20/20 HealthCare Partners LLC, Highlight Capital, Yonghua Capital.
- How much funding has Verseau Therapeutics raised?
- Verseau Therapeutics has disclosed $4.3M raised across 1 of its 2 known rounds.
- Where is Verseau Therapeutics headquartered?
- Verseau Therapeutics is headquartered in Auburndale, US.